According to the KEGG enrichment results, SGLT2 inhibitors' cardiorenal protection may be associated with Lipid and AS, MAPK signaling pathway, Ras-related Protein 1 (Rap1) signaling pathway, Endocrine resistance, Fluid shear stress, and atherosclerosis, tumor necrosis factor (TNF) signaling pathway, Relaxin signaling pathway, Neurotrophin signaling pathway, Advanced glycation end-products (AGEs)- receptor for advanced glycation end-products (RAGE) signaling pathway in diabetic complications. This evidence concerns the gene SLC5A2 and atherosclerosis.